Monopar Therapeutics Inc. Current Assets
Monopar Therapeutics Inc. (MNPR) had Current Assets of $134.76 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-12
- 2026-06-30: Assets, Current $134.76M.
- 2026-03-31: Assets, Current $137.74M.
- 2025-12-31: Assets, Current $140.46M.
- 2025-09-30: Assets, Current $144.09M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $134.76M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $137.74M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $140.46M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $144.09M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $53.75M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $55.08M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $60.29M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $6.07M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $7.18M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $8.91M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $7.33M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $8.57M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $10.30M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $11.78M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $13.17M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $14.37M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $16.65M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $18.01M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $20.52M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $22.45M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $24.39M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $25.84M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $16.80M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $18.09M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $12.73M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $12.72M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $13.23M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $5.11M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $5.60M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $6.35M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $7.25M 10-K · filed 2020-03-27 | $7.32M 10-K · filed 2019-02-26 |
| 2018-09-30 | $7.89M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $7.65M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $8.35M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $9.13M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $2.10M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |